SCHEMBL13199366

SCHEMBL13199366

COC(=O)c1ccc(Cn2c(=O)[nH]cc(F)c2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 3/20 0.46
P2RX3 P56373 1/20 0.44
LMNA P02545 2/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
HTT P42858 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.43
TP53 P04637 3/20 0.43
MAPT P10636 2/20 0.43
FAAH O00519 1/20 0.43
DRD2 P14416 2/20 0.42
TBXA2R P21731 2/20 0.42
GAA P10253 1/20 0.42
POLB P06746 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14471274 0.85 HSP90AA1 (0.46) HSP90AA1RAB9ANPC1TP53MAPT
SCHEMBL12657814 0.84 MEN1 (0.49) HSP90AA1TP53MAPTGAAPOLB
SCHEMBL10171783 0.81 KDM4E (0.51) HSP90AA1MAPTGAAPOLB
SCHEMBL11315740 0.75 HPGD (0.50) HSP90AA1LMNAHTTTP53MAPT
SCHEMBL7745468 0.72 LMNA (0.70) LMNAHTTTP53MAPTGAA
SCHEMBL11641243 0.72 DRD2 (0.56) DRD2TBXA2RGAA
SCHEMBL5205919 0.72 LMNA (0.47) P2RX3LMNARAB9ANPC1HTT
SCHEMBL3534743 0.72 LMNA (0.63) LMNAHTTMAPTDRD2TBXA2R
SCHEMBL4253579 0.72 GAA (0.65) HTTTP53MAPTGAAPOLB
SCHEMBL11400973 0.71 TDP1 (0.41) LMNARAB9ANPC1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9551724-B2 5-fluoro-uracil immunoassay SALADAX BIOMEDICAL, INC. (US) 2017-01-24 US disclosed
US-9551724-B2 5-fluoro-uracil immunoassay SALADAX BIOMEDICAL, INC. (US) 2017-01-24 US disclosed
EP-2280281-B1 5-fluoro-uracil immunoassay SALADAX BIOMEDICAL INC (US) 2014-05-21 EP disclosed
US-20100204456-A1 5-Fluoro-Uracil Immunoassay SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) 2010-08-12 US disclosed
US-7767794-B2 5-fluoro-uracil immunoassay SALADAX BIOMEDICAL INC (US) 2010-08-03 US disclosed
US-20070154972-A1 5-Fluoro-uracil immunoassay SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) 2007-07-05 US disclosed
US-7205116-B2 5-Fluoro-uracil immunoassay SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) 2007-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204456-A1 5-Fluoro-Uracil Immunoassay UNG, DPYD, DUT HSP90AA1 3147/4885P2RX3 3472/4885LMNA 4568/4885
US-20070154972-A1 5-Fluoro-uracil immunoassay UNG, DPYD, DUT HSP90AA1 3147/4885P2RX3 3472/4885LMNA 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.